Inactive

CDC awarded contract no. 75D30121C12706 to The Trustees Of Columbia University In The City Of New York (“Columbia”), 630 W 168th St Fl 4, New York, NY 10032-3725 on September 14, 2021, in the amount o... CDC awarded contract no. 75D30121C12706 to The Trustees Of Columbia University In The City Of New York (“Columbia”), 630 W 168th St Fl 4, New York, NY 10032-3725 on September 14, 2021, in the amount of $481,380.00. This notices makes available a justification and approval for other than full and open competition (JOFOC) that applies to this contract. This contract was awarded under the authority of FAR 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements. The purpose of this project is to prospectively enroll and follow hospitalized patients with neurological signs/symptoms and/or conditions and control patients; this would include patients with prior SARS-CoV-2 infection and patients who are recent COVID-19 vaccine recipients. The study will prospectively follow these patients for outcomes related to neurological signs/symptoms and/or conditions. The study will enroll patients who belong to critical populations, specifically minorities and those with low socioeconomic status. In addition, the project allows for the identification, definition, and classification of neurologic events possibly associated with the newly developed COVID vaccine(s). This could potentially allow for phenotypic differentiation for neurologic illness associated directly with the virus, versus those potentially associated with the vaccine(s). Columbia was determined to be the only responsible source and best acquisition option for the following reasons: Columbia has conducted a recent retrospective cohort investigation into the neurologic manifestations of COVID, which has successfully identified the most frequent neurologic complications of COVID, the basic laboratory parameters of such neuro-COVID patients, and discharge dispositions/immediate outcomes. Columbia is uniquely suited to do this work since they have been established collaborators of the CDC neuro-unit since 2020. Columbia serves a population vulnerable to COVID (older, ethnic minorities, socioeconomically vulnerable) and has the academic center support for data and specimen collection and analysis. COVID-19 neurologic illness continues to be an ongoing source of substantial morbidity and mortality with that associated with acute SARS-CoV-2 infection, and in the coming weeks and months it is going to be critical to assess the long-term outcomes of COVID-19 through the perspective of a neurological illness. Columbia will require minimal, if any, start-up time and costs for this project. The attached JOFOC is being made available within 14 days of the contract award in accordance with FAR 6.305(a) and will remain active for 30 days in accordance with FAR 6.305(d)(3).